Digital phenotyping in young breast cancer patients treated with neoadjuvant chemotherapy (the NeoFit Trial): protocol for a national, multicenter single-arm trial.
Fiche publication
Date publication
mai 2022
Journal
BMC cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr JOUANNAUD Christelle
Tous les auteurs :
Delrieu L, Hamy AS, Coussy F, Kassara A, Asselain B, Antero J, De Villèle P, Dumas E, Forstmann N, Guérin J, Hotton J, Jouannaud C, Milder M, Leopold A, Sedeaud A, Soibinet P, Toussaint JF, Vercamer V, Laas E, Reyal F
Lien Pubmed
Résumé
Breast cancer (BC) has particular characteristics in young women, with diagnosis at more advanced stages, a poorer prognosis and highly aggressive tumors. In NeoFit, we will use an activity tracker to identify and describe various digital profiles (heart rate, physical activity, and sleep patterns) in women below the age of 45 years on neoadjuvant chemotherapy for BC.
Mots clés
Activity trackers, Breast cancer, Digital, Neoadjuvant, Prevention
Référence
BMC Cancer. 2022 May 4;22(1):493